| Description |
1 online resource (313 pages) : illustrations. |
|
text txt rdacontent |
|
computer c rdamedia |
|
online resource cr rdacarrier |
| Series |
Pharmacology - research, safety testing and regulation |
|
Pharmacology-research, safety testing, and regulation series.
|
| Note |
Online resource; title from PDF title page (ebrary, viewed December 16, 2013). |
| Bibliography |
Includes bibliographical references and index. |
| Summary |
This book, published in two volumes, Volume 1 and Volume 2, respectively, represents the most comprehensive and up-to-date collection of current literature on angiotensin inhibition and related topics in medicine, nephrology and cardiovascular medicine ever compiled. Top experts in the various fields of nephrology, hypertension, cardiovascular medicine, pharmacotherapeutics and related fields from all five continents have contributed essays, original papers, reviews and editorial opinions to this volume. This book has turned out to be the most authoritative reference source on ACEIs, with cont. |
| Contents |
ACE INHIBITORS: MEDICAL USES, MECHANISMS OF ACTION, POTENTIAL ADVERSE EFFECTS AND RELATED TOPICS. VOLUME 1; ACE INHIBITORS: MEDICAL USES, MECHANISMS OF ACTION, POTENTIAL ADVERSE EFFECTS AND RELATED TOPICS. VOLUME 1; Library of Congress Cataloging-in-Publication Data; Contents; Special Preview; Foreword; Preface; Volume 1; Volume 2; References; Acknowledgments; Cognitive Drift Poem; The EMR and Cognitive Drift -- Click, Click, Click. And Only More Clicks; Reference; Section 1. Introduction to ACE Inhibitors and Angiotensin Receptor Blockers in Clinical Medicine. |
|
Chapter 1: The Introduction of Angiotensin Converting Enzyme Inhibitors (ACEIs) and Angiotensin Receptor Blockers (ARBs) into Clinical Medicine and the Mechanisms of Actions of ACEIs and ARBsAbstract; Introduction; The Discovery of Captopril; The Generation of Angiotensin II by ACE; The Introduction of ACEIs and ARBs into Clinical Medicine -- Clinical Effects, Mechanisms of Actions, Indications and Medical Uses; Conclusion; References; Section 2. ACE Inhibitors, Angiotensin Receptor Blockers, Chronic Kidney Disease, Randomized Controlled Trials and the Nephrology Literature. |
|
Chapter 2: RCTs Revisited: A Nephrologist's Critique of Randomized Controlled Trials in the Nephrology LiteratureAbstract; Introduction; Assessment of Differences; How to Determine the Stochastic Difference?; Randomized Controlled Trials; Observational Studies; Before-and-After Designs; Statistical Methods in Dialysis; Observational Studies; Before-and-After Designs; Randomized Controlled Studies in Dialysis; Conclusion; References; Chapter 3: The Abuse of Renal Surrogates and Combination Renal Endpoints in Nephrology RCTs; 1Mayo Clinic College of Medicine, Rochester, MN, US. |
|
2Department of Nephrology, Mayo Clinic Health System, Eau Claire, WI, USAbstract; Commentary; Conclusion; References; Chapter 4: The CKD Enigma, Reengineering CKD Care, Narrowing Asymmetric Information and Confronting Ethicomedicinomics in CKD Care: The Introduction of the New 'CKD Express©' IT Software Program; 1Mayo Clinic College of Medicine, Rochester, MN, US; 2Department of Nephrology, Mayo Clinic Health System, Eau Claire, WI, US; 3Department of Materials' Science, Northwestern University, Evanston, IL, US; 4Department of Science Technology Society, Stanford University, Stanford, CA, US. |
|
5Nuclear Weapons Center, Kirtland AirForce Base, Albuquerque, NM, US6NTEC Solutions LLC, Eau Claire, WI, US; 7Department of Healthcare Informatics, Mayo Clinic Health System, Eau Claire, WI, US; 8Information Technology, Nurture Healthcare Service LLC, Houston, TX, US; Abstract; Introduction; 1. Asymmetric Information (AI); An Everyday Example of Asymmetric Information; 2. Complex Adaptive System; 3. Ethicomedicinomics; 4. Process Management; 5. Reengineering; 6. The CKD Enigma; Development of "the CKD Express©" -- An Innovative IT CKD-Specific Software Program; Discussion. |
| Subject |
Angiotensin converting enzyme -- Inhibitors.
|
|
Hypertension -- Chemotherapy.
|
|
Angiotensin-Converting Enzyme Inhibitors |
|
Enzyme de conversion de l'angiotensine -- Inhibiteurs.
|
|
Hypertension artérielle -- Chimiothérapie.
|
|
HEALTH & FITNESS -- Diseases -- General.
|
|
MEDICAL -- Clinical Medicine.
|
|
MEDICAL -- Diseases.
|
|
MEDICAL -- Evidence-Based Medicine.
|
|
MEDICAL -- Internal Medicine.
|
|
Angiotensin converting enzyme -- Inhibitors
|
|
Hypertension -- Chemotherapy
|
| Added Author |
Onuigbo, Macaulay Amechi, editor.
|
| Other Form: |
Print version: Onuigbo, Macaulay Amechi. ACE Inhibitors : Medical Uses, Mechanisms of Action, Potential Adverse Effects and Related Topics. Volume 1. New York : Nova Science Publishers, Inc., ©1900 9781629483832 |
| ISBN |
9781629484372 (electronic bk.) |
|
1629484377 (electronic bk.) |
|
9781629483832 |
| Standard No. |
AU@ 000055946886 |
|
